Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Otenaproxesul and COVID-19 Data

<< Previous

Bullboard Posts

Next >>

Comment by Rarbar99on Aug 19, 2021 1:05pm

110 Views

Post# 33731017

RE:RE:RE:RE:RE:RE:RE:Otenaproxesul and COVID-19 Data

For the second time, selling is not an option for a company during these dips. It would almost be like declaring bankruptcy. They will never do this even if they wanted too.

But I looked through your profile and you were arguing with Yukon for several months. In the end, he was right and you were wrong. Take it like a champ and stop crying. Things haven't been going too well for you, sucks to suck.

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity